[Use of pronoran (piribedil) in Parkinson's disease: the results of a multicenter study].
The study of 99 patients has been conducted in 5 Russian centers. Pronoran ("Servier", France) combined with levodopa was used in dosage 50-150 mg daily during 6 months. The treatment was placebo-controlled. Significant differences (p < 0.001) between the study and control groups in expression of all main symptoms of the disease were found.
Fedorova
N V
NV
D000978:Antiparkinson Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D015259:Dopamine Agents / Q000008:administration & dosage / Q000627:therapeutic use; D018491:Dopamine Agonists / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D006801:Humans; D007980:Levodopa / Q000008:administration & dosage / Q000627:therapeutic use; D010300:Parkinson Disease / Q000188:drug therapy*; D010891:Piribedil / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D010919:Placebos; D013997:Time Factors; D016896:Treatment Outcome
D000978:Antiparkinson Agents; D015259:Dopamine Agents; D018491:Dopamine Agonists; D010919:Placebos; D007980:Levodopa; D010891:Piribedil